Malaria drug combo shows promise against COVID-19 in early trial
NCT ID NCT04339426
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of atovaquone (an anti-malarial) and azithromycin (an antibiotic) can clear the COVID-19 virus in infected adults. The study enrolls people at high risk for complications, such as those with moderate to severe illness. Participants receive the drugs for up to 10 days, and researchers measure how many achieve an undetectable viral load.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atovaquone and azithromycin
What this could lead to
If successful, this combination could offer a new treatment option to clear COVID-19 infection in high-risk patients.
What could go wrong
This is a very small, early-phase trial with only 3 participants, so results may not apply broadly. The drugs can cause gastrointestinal side effects and heart rhythm changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth
Scottsdale, Arizona, 85258, United States